Sequencing of hormonal therapy in breast cancer.
Hormonal therapy plays an integral role in the management of the majority of women with breast cancer who can be considered to have hormone-dependent breast cancer because of the presence of the molecular predictive markers, estrogen receptor and progesterone receptor. Numerous hormonal agents are available from multiple classes of drugs, including selective estrogen receptor modulators, aromatase inhibitors, progestins, androgens, and luteinizing hormone-releasing hormone analogues. Multiple clinical trials involving these agents have been conducted which permit an evidence-based approach to the development of a sequencing strategy for treatment of women with breast cancer.
Ingle
James N
JN
Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA. ingle.james@mayo.edu
D000368:Aged; D000728:Androgens / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use*; D047072:Aromatase Inhibitors; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D004334:Drug Administration Schedule; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D017698:Postmenopause / Q000187:drug effects; D017697:Premenopause / Q000187:drug effects; D011372:Progestins / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D011966:Receptors, LHRH / Q000187:drug effects; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use
D000728:Androgens; D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D004791:Enzyme Inhibitors; D011372:Progestins; D011966:Receptors, LHRH; D020845:Selective Estrogen Receptor Modulators